EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds
On Tuesday, Clearmind Medicine Inc (NASDAQ:CMND) submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd (NASDAQ:SPRC). The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), Ibogaine, and Ketamine, each with Palmitoylethanolamide (PEA), the active ingredient of SciSparc’s proprietary CannAmide. These were previously filed as provisional pate
Source: yahoo.com
